MEDIUMBuilt-inGeographic
China
“10-K Item 1A: 'A significant portion of our revenue is derived from sales into China... Our revenue in China for the year ended December 31, 2025, was $475.8 million'”
BRKR · Concentration risk · 10-K extracted
Bruker (BRKR) concentration risks
Updated
The most significant concentration Bruker discloses is China, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Bruker’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH0
MEDIUM2
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMOutside partyCustomer
U.S. academic and government-funded customers
“10-K Item 1A: 'A meaningful portion of our revenue is derived from U.S. academic institutions, research organizations and other entities that rely in part on U.S. academic and government funding'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile comprises two geographic and customer-type exposures, each of moderate share by disclosed size and each structural or dependency in character. China is identified as a significant source of revenue: the company's revenue from China for the year ended December 31, 2025, was $475.8 million, a moderate-share geographic exposure. This is structural in character in that it follows where the global scientific instrumentation market's end-user base sits, but it carries elevated sensitivity to export controls, bilateral trade tensions, and government-directed procurement shifts in that market. The second exposure involves U.S. academic and government-funded customers — institutions that rely in part on U.S. academic and government funding — a moderate dependency exposure by disclosed size. Unlike a commercial customer relationship, this dependency is sensitive to federal budget cycles, grant-funding availability, and policy decisions around research spending rather than to any single purchasing entity. A reduction in federal research appropriations or a shift in grant priorities could compress demand from this customer segment without the company having direct contractual recourse. The two exposures are largely independent of each other, affecting different geographies and funding sources, which means they are unlikely to move in the same direction simultaneously. Neither is dominant on its own, but together they describe a business where two meaningful revenue channels each carry a specific policy or geopolitical sensitivity that is worth monitoring separately from broader volume and pricing dynamics.
For the engine’s reasoning on BRKR’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| BRKR● | Bruker Corporation | 0 | 2 | 0 | 2 |
| AXGN | AxoGen, Inc. | 0 | 0 | 0 | 0 |
| BIO | Bio-Rad Laboratories, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.